[1] Sanlorenzo M, Vujic I, Posch C, et al. Melanoma immunotherapy[J]. Cancer Biol Ther, 2014, 15(6):85-92. [2] Shaw PC, Chan WL, Yeung HW, et al. Minireview:Trichosanthin-a protein with multiple pharmacological properties[J]. Life Sci, 1994, 55(4):253-262. [3]Wang P, Xu J, Zhang C, et al. CREB, a possible upstream regulator of Bcl-2 in Trichosanthin -induced Hela cell apoptosis[J]. Mol Biol Rep, 2010, 37(4):1891-1896. [4]熊高准, 楼建国. 天花粉蛋白对结肠癌SW-620细胞株增殖、黏附和迁移的实验研究[J]. 中成药, 2012, 34(3):434-439. [5]赵爽, 郝雪峰. 根癌农杆菌介导天花粉蛋白基因TCS转化茎瘤芥的研究[J]. 生物技术通报, 2010(3):124-127. [6]郭栋, 韩冰冰. 天花粉蛋白对黑色素瘤细胞黏附、迁移及侵袭能力的影响[J]. 辽宁中医杂志, 2013, 40(9):1932-1935. [7]Rong B, Yang S, Li W, et al. Systematic review and meta-analysis of Endostar combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer[J]. World J Surg Oncol, 2012, 24(10):170. [8]Rosca EV, Koskimaki JE, Rivera CG, et al. Anti-angiogenic peptides for cancer therapeutics[J]. Curr Pharm Biotechnol, 2011, 12(8):1101-1116. [9]Fang EF, Zhang CZY, Zhang L, et al. Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis[J]. PLoS One, 2012, 7(9):e41592. [10]Cai YC, Xiong SD, Zheng YJ, et al. Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM[J]. Cellular & Molecular Immunology, 2011, 8:359-367. [11]Eisenberg S. Biologic therapy[J]. Journal of Infusion Nursing, 2012, 35(5):301-314. [12]Kontermann RE. Antibody-cytokine fusion proteins[J]. Archives of Biochemistry and Biophysics, 2012, 526:194-205. [13]Drake CG. Combination immunotherapy approaches[J]. Annals of Oncology, 2012, 23(8):41-46. [14]Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy[J]. Cancer Immunol Immunother, 2009, 58:317-332.
|